• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Researchers find way to better use current drugs to target cancer

Bioengineer by Bioengineer
June 22, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: McMaster University

Hamilton, ON (June 22, 2017) — A team of researchers at McMaster University has identified a unique feature of cancer stem cells that can be exploited to kill the deadly cells thought to be the reason that cancer comes back after therapy. Understanding this feature will be useful for delivering more targeted cancer therapeutics to the right patients.

The study, published today in the scientific journal Cell Chemical Biology, reveals that an existing set of drugs is effective in killing cancer stem cells and explains how this led the team to uncovering important details about how these cells are working in human tumors.

"The drugs helped us to understand the biology," said Mick Bhatia, principal investigator of the study and scientific director of the McMaster Stem Cell and Cancer Research Institute. "We've worked backwards, employing a series of drugs used in the clinic to understand a new way that cancer stem cells can be killed."

The researchers found that a particular protein, called Sam68, is an important actor in cancer stem cells, and that this protein allows existing drugs to work on cancer cells, causing them to die.

Bhatia hopes that this information can be used to deliver targeted therapies to the patients who would benefit from them, while sparing others from unhelpful treatments. He believes that treatment of blood cancers like leukemia and other cancers such as prostate, colon and renal will follow the example set in breast cancer, where patients receive treatments tailored to their specific form of the disease.

"In the case of breast cancer, other researchers have found new ways to make existing drugs more effective by only giving them to people who were likely to benefit based on their specific traits and using drugs that target these traits," Bhatia said.

He said while developing a new drug takes an average of about 15 years and comes with a price tag in the hundreds of millions, defining the role of existing drugs to use them better in patients will help to accelerate the process of bringing the right drugs to the right people.

###

The study was supported by the Canadian Institutes of Health Research, the Canadian Cancer Society Research Institute, the Canada Research Chairs program, the Fonds de Recherche en Sante du Quebec, the Cancer Research Society.

Editors: Pictures of researchers of the McMaster Stem Cell and Cancer Research Institute and an illustration of human stem cells stained for the Sam68 protein are available here: https://fhs.mcmaster.ca/media/cell_chemical_biology

To book an interview, please contact:

Veronica McGuire
Media Relations Co-ordinator
Faculty of Health Sciences
McMaster University
T: (905) 525-9140, ext. 22169
[email protected]

Media Contact

Veronica McGuire
[email protected]
905-525-9140 x22169
@mcmasteru

Home

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Clonal Follicular CD4+ T Cells Adapt Across Lymph Nodes and Lung Tumors

August 21, 2026

Tobacco Firms Overwhelmed Federal Comments, Delaying Proposed Menthol Cigarette Ban

August 21, 2026

Durable hydrogen catalyst operates continuously for 3,000 hours

August 21, 2026

Scientists warn free-to-play games hide high costs, urging stronger player protections

August 21, 2026
Please login to join discussion

POPULAR NEWS

  • Clonal Follicular CD4+ T Cells Adapt Across Lymph Nodes and Lung Tumors

    29 shares
    Share 12 Tweet 7
  • Tobacco Firms Overwhelmed Federal Comments, Delaying Proposed Menthol Cigarette Ban

    29 shares
    Share 12 Tweet 7
  • Durable hydrogen catalyst operates continuously for 3,000 hours

    29 shares
    Share 12 Tweet 7
  • Scientists warn free-to-play games hide high costs, urging stronger player protections

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Clonal Follicular CD4+ T Cells Adapt Across Lymph Nodes and Lung Tumors

Tobacco Firms Overwhelmed Federal Comments, Delaying Proposed Menthol Cigarette Ban

Durable hydrogen catalyst operates continuously for 3,000 hours

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.